14
Participants
Start Date
May 11, 2020
Primary Completion Date
June 27, 2023
Study Completion Date
November 3, 2023
All patients in the study will be treated with ocrelizumab
300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
Providence Neurological Specialties West, Portland
Swedish Medical Center Multiple Sclerosis Center, Seattle
Collaborators (2)
Institute for Systems Biology
OTHER
Genentech, Inc.
INDUSTRY
Providence Health & Services
OTHER